Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration

Lucid Diligence Brief: Earendil Labs & WuXi XDC collaboration Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics autoimmune deal

Lucid Diligence Brief: Boehringer Ingelheim & Sitryx Therapeutics…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Turbine $25m Series B for virtual biology

Lucid Diligence Brief: Turbine $25m Series B for virtual biology Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Astellas collaboration with Vir Biotechnology

Lucid Diligence Brief: Astellas collaboration with Vir Biotechnology…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Angelini Pharma collaboration with Quiver Bioscience on genetic epilepsies

Lucid Diligence Brief: Angelini Pharma collaboration with Quiver Bioscience on…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel)

Lucid Diligence Brief: Gilead to acquire Arcellx (anito-cel) Professional…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Hims & Hers to acquire Eucalyptus

Lucid Diligence Brief: Hims & Hers to acquire Eucalyptus Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir in COPD

Lucid Diligence Brief: Altesa BioSciences $75 million Series B for vapendavir…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Unnatural Products Novartis macrocyclic peptide licensing agreement

Lucid Diligence Brief: Unnatural Products Novartis macrocyclic peptide…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Danaher to acquire Masimo in $9.9bn all-cash deal

Lucid Diligence Brief: Danaher to acquire Masimo in $9.9bn all-cash deal…


Privacy Preference Center